Ocular Therapeutix, Inc.
OCUL
$7.45
-$0.49-6.17%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 17.08M | 15.43M | 16.44M | 14.77M | 14.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.08M | 15.43M | 16.44M | 14.77M | 14.80M |
| Cost of Revenue | 42.22M | 38.62M | 30.37M | 22.06M | 17.58M |
| Gross Profit | -25.14M | -23.19M | -13.93M | -7.29M | -2.78M |
| SG&A Expenses | 25.44M | 22.81M | 29.67M | 24.33M | 17.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 67.66M | 61.42M | 60.03M | 46.39M | 34.85M |
| Operating Income | -50.58M | -46.00M | -43.59M | -31.62M | -20.05M |
| Income Before Tax | -48.39M | -36.49M | -43.78M | -64.85M | -29.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -48.39M | -36.49M | -43.78M | -64.85M | -29.22M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.39M | -36.49M | -43.78M | -64.85M | -29.22M |
| EBIT | -50.58M | -46.00M | -43.59M | -31.62M | -20.05M |
| EBITDA | -49.62M | -45.04M | -42.63M | -30.70M | -19.09M |
| EPS Basic | -0.29 | -0.22 | -0.26 | -0.49 | -0.35 |
| Normalized Basic EPS | -0.18 | -0.14 | -0.17 | -0.17 | -0.22 |
| EPS Diluted | -0.29 | -0.22 | -0.26 | -0.49 | -0.35 |
| Normalized Diluted EPS | -0.18 | -0.14 | -0.17 | -0.17 | -0.22 |
| Average Basic Shares Outstanding | 168.02M | 166.99M | 165.82M | 132.02M | 84.43M |
| Average Diluted Shares Outstanding | 168.02M | 166.99M | 165.82M | 132.02M | 84.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
